Dr. Kuriakose will step into the role May 1, according to a March 27 news release. He joins Terns Oncology from Calithera Biosciences, where he served as chief medical officer and led two mid-stage clinical programs.
Dr. Kuriakose also has experience leading the global clinical program at the Cambridge, Mass.-based Novartis Institutes for BioMedical Research and as medical director of Novartis Oncology, where he designed and executed oncology trials.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.